目的: 探究嗅觉蛋白样2B蛋白(OLFML2B)在结肠癌组织中的表达。方法: 通过TCGA数据库分析OLFML2B在泛癌中的基因表达差异。收集结肠癌患者的癌组织及其癌旁正常组织样本,通过免疫组织化学法和蛋白质印迹实验检测OLFML2B、磷酸化蛋白激酶B(p-AKT)、转录因子MYB以及细胞周期蛋白D1(CCND1)在这些组织中的表达水平,分析这些蛋白在结肠癌发展中可能存在的潜在联系。结果: 在泛癌研究中,OLFML2B的表达在各种肿瘤组织中存在明显差异,其在多种肿瘤组织中高表达,如结肠癌、肺腺癌、肾透明细胞癌、胃腺癌、肝细胞癌等(P＜0.05)。在TCGA-COAD配对样本中,OLFNL2B在结肠癌中高表达。免疫组织化学法和蛋白免疫印记实验检测发现,在结肠癌组织中,OLFML2B、p-AKT、MYB和CCND1的表达水平显著高于癌旁正常组织(P＜0.05)。Spearman相关性分析表明,在结肠癌中OLFML2B与p-AKT、MYB、CCND1的表达呈正相关(P﹤0.05)。结论: OLFML2B、p-AKT、MYB、CCND1在结肠癌中高表达,可能通过相互作用促进了癌症的发生发展,其作用机制可能与磷脂酰肌醇-3-羟激酶(PI3K/Akt)信号通路有关。
Objective: To investigate the expression of olfactory protein-like 2B (OLFML2B) in colon cancer tissues. Methods: The gene expression difference of OLFML2B in pan-cancer was analyzed by TCGA database. The expression levels of OLFML2B, phosphorylated protein kinase B (p-AKT), transcription factor MYB and cyclin D1 (CCND1) in cancer tissues and adjacent normal tissues of patients with colon cancer were detected by immunohistochemistry and Western blotting, and the potential links of these proteins in the development of colon cancer were analyzed. Results: In the pan-cancer study, the expression of OLFML2B was significantly different in various tumor tissues, and it was highly expressed in a variety of tumor tissues, such as colon cancer, lung adenocarcinoma, renal clear cell carcinoma, gastric adenocarcinoma, hepatocellular carcinoma, etc. (P＜0.05). In TCGA-COAD paired samples, OLFNL2B was highly expressed in colon cancer. Immunohistochemistry and Western blot analysis showed that the expression levels of OLFML2B, p-AKT, MYB and CCND1 in colon cancer tissues were significantly higher than those in adjacent normal tissues (P＜0.05). Spearman correlation analysis showed that OLFML2B was positively correlated with the expression of p-AKT, MYB and CCND1 in colon cancer (P＜0.05). Conclusion: OLFML2B, p-AKT, MYB and CCND1 are highly expressed in colon cancer, which may promote the occurrence and development of cancer through interaction, and its mechanism may be related to phosphatidylinositol-3-hydroxykinase (PI3K/Akt) signaling pathway.
[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Barembaum M, Moreno TA, Labonne C, et al.Noelin-1 is a secreted glycoprotein involved in generation of the neuralcrest[J].Nat Cell Biol, 2000, 2(4): 219-225.
[3] 李志龙.OLFML2B促进肾癌细胞增殖迁移的研究[D].南昌:南昌大学, 2022.
[4] Lin J, Xu X, Li T, et al.OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide [6]Screening: A Study Based on Seven Cohorts[J].Front Oncol, 2021, 11: 650678.
[5] Zhao X, Tang Y, Ren H, et al.Identification of Prognosis-Related Genes in Bladder Cancer Microenvironment across TCGA Database[J].Biomed Res Int, 2020, 20: 9143695.
[6] Yang Y, Deng X, Chen X, et al.Landscape of active enhancers developed de novo in cirrhosis and conserved in hepatocellular carcinoma[J].Am J Cancer Res, 2020, 10(10): 3157-3178.
[7] Liu J, Liu Z, Zhang X, et al.Bioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing tools[J].BMC Cancer, 2019, 19(1): 227.
[8] Sistani L, Rodriguez PQ, Hultenby K, et al.Neuronal proteins are novel components of podocyte major processes and their expression in glomerular crescents supports their role in crescent formation[J].Kidney Int, 2013, 83(1): 63-71.
[9] Hu P, Zhang X, Li Y, Xu L, Qiu H.Pan-Cancer Analysis of OLFML2B Expression and Its Association With Prognosis and Immune Infiltration[J].Front Genet, 2022, 13: 882794.
[10] Xu JC, Chen TY, Liao LT, et al.NETO2 promotes esophageal cancer progressionby inducing proliferation and metastasis via PI3K/AKT and ERK pathway[J].Int J Biol Sci, 2021, 17(1): 259-270.
[11] Feng J, Xie G, Zhan Y, et al.Elevated HSP90 associates with expression of HIF-1alpha and p-AKT and is predictive of poor prognosis in nasopharyngeal carcinoma[J].Histopathology, 2019, 75(2): 202-212.
[12] Ciruelos Gil EM.Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer[J].Cancer Treat Rev, 2014, 40(7):862-871.
[13] Fattahi S, Amjadi-Moheb F, Tabaripour R, et al.PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond[J].Life Sci, 2020,262: 118513.
[14] Yao H, Su S, Xia D, et al.F-box and leucine-rich repeat protein 5 promotes colon cancer progression by modulating PTEN/PI3K/Akt signaling pathway[J].Biomed Pharmacother, 2018, 107: 1712-1719.
[15] Guo Y, Zhang Y, Gerhard M, et al.Effect of Helicobacter pylori on gastrointestinal microbiota:a population-based study in Linqu, a high-risk area of gastric cancer[J].Gut, 2020, 69(9): 1598-1607.
[16] Marcolino TF, Pimenta CAM, Artigiani Neto R, et al.p53, Cyclin-D1, beta-catenin, APC and c-myc in tumor tissue from colorectal and gastric cancer patients with suspected lynch syndrome by the bethesda criteria[J].Asian Pac J Cancer Prev, 2020, 21(2): 343-348.
[17] Feng YF, Qian WW, Zhang Y, et al.CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo[J].BMC Cancer, 2019, 19(1): 576.
[18] George OL, Ness SA.Situational awareness:regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis[J].Cancers(Basel), 2014, 6(4): 2049-2071.
[19] 胡明亮, 王强.转录因子MYB激活CTSF通过谷氨酰胺代谢影响胃癌细胞增殖和细胞干性[J].中国医科大学学报, 2024, 53(5):405-413.
[20] Qu X, Yan X, Kong C, et al.C-Myb promotes growth and metastasis of colorectal cancer through c-fos-induced epithelial-mesenchymal transition[J].Cancer Sci, 2019, 110(10): 3183-3196.
